Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes

被引:547
作者
Lavinsky, RM
Jepsen, K
Heinzel, T
Torchia, J
Mullen, TM
Schiff, R
Del-Rio, AL
Ricote, M
Ngo, S
Gemsch, J
Hilsenbeck, SG
Osborne, CK
Glass, CK
Rosenfeld, MG
Rose, DW
机构
[1] Univ Calif San Diego, Dept Med, Whittier Diabet Program, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Grad Program Biol, Sch Med, Dept Med, La Jolla, CA 92093 USA
[4] Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78284 USA
关键词
estrogen receptor; tamoxifen; corepressor complex;
D O I
10.1073/pnas.95.6.2920
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain, Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, positively or negatively, by diverse signal transduction pathways, Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer. Our data suggest that N-CoR- and SMRT-containing complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.
引用
收藏
页码:2920 / 2925
页数:6
相关论文
共 50 条
[31]   Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase [J].
Nagy, L ;
Kao, HY ;
Chakravarti, D ;
Lin, RJ ;
Hassig, CA ;
Ayer, DE ;
Schreiber, SL ;
Evans, RM .
CELL, 1997, 89 (03) :373-380
[32]   The transcriptional coactivators p300 and CBP are histone acetyltransferases [J].
Ogryzko, VV ;
Schiltz, RL ;
Russanova, V ;
Howard, BH ;
Nakatani, Y .
CELL, 1996, 87 (05) :953-959
[33]  
ONATE SA, 1995, SCIENCE, V270, P1354
[34]   MECHANISMS OF TAMOXIFEN RESISTANCE [J].
OSBORNE, CK ;
FUQUA, SAW .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 32 (01) :49-55
[35]   ACQUIRED TAMOXIFEN RESISTANCE - CORRELATION WITH REDUCED BREAST-TUMOR LEVELS OF TAMOXIFEN AND ISOMERIZATION OF TRANS-4-HYDROXYTAMOXIFEN [J].
OSBORNE, CK ;
CORONADO, E ;
ALLRED, DC ;
WIEBE, V ;
DEGREGORIO, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (20) :1477-1482
[36]  
Osborne CK, 1996, SCI AM SCI MED, V3, P32
[37]  
OSBORNE CK, 1995, J NATL CANCER I, V87, P46
[38]   What's up and down with histone deacetylation and transcription? [J].
Pazin, MJ ;
Kadonaga, JT .
CELL, 1997, 89 (03) :325-328
[39]   EXPRESSION OF C-FOS AND AP-1 ACTIVITY IN SENESCENT HUMAN FIBROBLASTS IS NOT SUFFICIENT FOR DNA-SYNTHESIS [J].
ROSE, DW ;
MCCABE, G ;
FERAMISCO, JR ;
ADLER, M .
JOURNAL OF CELL BIOLOGY, 1992, 119 (06) :1405-1411
[40]   AN AMINO-TERMINAL DOMAIN OF MXI1 MEDIATES ANTI-MYC ONCOGENIC ACTIVITY AND INTERACTS WITH A HOMOLOG OF THE YEAST TRANSCRIPTIONAL REPRESSOR SIN3 [J].
SCHREIBERAGUS, N ;
CHIN, L ;
CHEN, K ;
TORRES, R ;
RAO, G ;
GUIDA, P ;
SKOULTCHI, AI ;
DEPINHO, RA .
CELL, 1995, 80 (05) :777-786